OptimizeRx Corporation ( OPRX ) NASDAQ Capital Market

Cena: 13.43 ( 2.36% )

Aktualizacja 07-03 22:00
NASDAQ Capital Market
Branża: Medical - Healthcare Information Services
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Healthcare Information Services
Zatrudnienie: 135
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 88%
Ilość akcji: 18 152 500
Debiut giełdowy: 2007-11-28
WWW: https://www.optimizerx.com
CEO: Mr. William J. Febbo
Adres: 400 Water Street
Siedziba: 48307 Rochester
ISIN: US68401U2042
Opis firmy:

OptimizerX Corporation, cyfrowa firma zajmująca się technologią zdrowia, zapewnia różne rozwiązania organizacji nauk przyrodniczych, świadczeniodawców i pacjentów. Produkty i aplikacje firmy obejmują wiadomości finansowe, wirtualne centrum wsparcia pacjenta, które pozwala lekarzom i personelowi uzyskać dostęp do próbek kuponów, kupony współpłacenia i inne wsparcie pacjentów za pośrednictwem systemów EMR i/lub e-odprawy; oraz świadomość marki i usługi przesyłania komunikatów o wsparciu terapeutycznym, takie jak komunikaty o świadomości marki, reklamy przypominające oraz wsparcie terapeutyczne i niezbadane wiadomości. Oferuje również usługi wsparcia marki, które koncentrują się na edukacji i współpracy z producentami farmaceutycznymi w zakresie identyfikacji, formułowania i wdrażania strategii ERX Media, w tym integracji plików leków, szkolenia sił sprzedaży i usług rozwoju strategii w celu promowania ich produktów. Ponadto firma prowadzi mobilną platformę komunikacyjną Mobile Health, która zapewnia interaktywne wiadomości zdrowotne w celu zwiększenia przestrzegania leków i koordynacji opieki; oraz zautomatyzowana platforma przesyłania wiadomości mobilnych zgodnych z HIPAA, która pozwala producentom farmaceutycznym i powiązanym podmiotom bezpośrednio zaangażowanie się z pacjentami w celu zwiększenia zgodności schematu. Ponadto oferuje programy pacjentów z informacjami o leczeniu i przystępności cenowej, stylu życia i kondycji, łączność urządzeń internetowych, formularze i ankiety. Ponadto firma zapewnia oparte na dowodach rozwiązanie zaangażowania lekarzy zastosowane do danych rzeczywistych, aby pomóc świadczeniodawcom w identyfikowaniu pacjentów, którzy mogą być kwalifikowani do określonych terapii, zwiększają świadomość ścieżek dostępu pacjentów i identyfikuj wczesne wskaźniki braku uzgodnienia wśród populacji pacjentów. Oferuje również inicjację terapii, koncentrując się na przyspieszeniu dostępu pacjentów do leczenia, w którym czasochłonna dokumentacja medyczna jest wymagana od HCP przed aptekami wydawającymi przepisane leki. Firma została znaleziona w 2006 roku i ma siedzibę w Rochester w stanie Michigan.

Wskaźniki finansowe
Kapitalizacja (USD) 248 389 193
Aktywa: 165 199 000
Cena: 13.43
Wskaźnik Altman Z-Score: 0.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -16.0
Ilość akcji w obrocie: 88%
Średni wolumen: 290 144
Ilość akcji 18 495 100
Wskaźniki finansowe
Przychody TTM 88 179 946
Zobowiązania: 50 734 000
Przedział 52 tyg.: 3.78 - 15.71
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.8
P/E branży: 32.4
Beta: 1.317
Raport okresowy: 2025-08-06
WWW: https://www.optimizerx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. William J. Febbo Chief Executive Officer & Director 863 150 1969
Mr. Edward Stelmakh C.M.A., M.B.A. Chief Financial Officer & Chief Operating Officer 626 738 1966
Mr. Stephen L. Silvestro President 591 621 1978
Mr. Terence J. Hamilton Senior Vice President of Pharma 441 632 1965
Ms. Marion K Odence-Ford General Counsel & Chief Compliance Officer 428 117 1965
Maira Alejandra Media Relations Manager 0 0
Ms. Theresa Greco Chief Commercial Officer 0 0
Dr. Doug Besch Chief Product Officer 0 1982
Ms. Sheryl Kearney Human Resources Manager 0 0
Mr. Andrew Jacob D'Silva Senior Vice President of Corporate Finance 0 0
Wiadomości dla OptimizeRx Corporation
Tytuł Treść Źródło Aktualizacja Link
OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2025-05-16 11:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Steve Silvestro - Chief Executive Officer Edward Stelmakh - Chief Financial Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Ryan Daniels - William Blair David Grossman - Stifel Richard Baldry - ROTH Capital Maxwell Michaelis - Lake Street Capital Markets Constantine Davides - Citizen Jeff Garro - Stephens Operator Good afternoon, everyone, and thank you for joining OptimizeRx First Quarter Fiscal 2025 Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro, he's joined by Chief Financial Officer; Ed Stelmakh; Chief Legal Officer, Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva. seekingalpha.com 2025-05-13 01:56:12 Czytaj oryginał (ang.)
OptimizeRx Corp. (OPRX) Beats Q1 Earnings and Revenue Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.11 per share a year ago. zacks.com 2025-05-12 22:35:37 Czytaj oryginał (ang.)
OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. globenewswire.com 2025-05-12 20:05:00 Czytaj oryginał (ang.)
OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. globenewswire.com 2025-05-01 20:05:00 Czytaj oryginał (ang.)
OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. globenewswire.com 2025-04-23 11:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the “Board”), it intends to appoint a new independent director to its Board of Directors during the second half of this year. globenewswire.com 2025-04-18 20:15:00 Czytaj oryginał (ang.)
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million. benzinga.com 2025-03-12 13:56:42 Czytaj oryginał (ang.)
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call. seekingalpha.com 2025-03-12 13:04:09 Czytaj oryginał (ang.)
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago. zacks.com 2025-03-12 11:45:22 Czytaj oryginał (ang.)
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-03-12 09:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders. globenewswire.com 2025-03-11 09:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team globenewswire.com 2025-03-10 09:30:00 Czytaj oryginał (ang.)
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call. globenewswire.com 2025-02-27 09:30:00 Czytaj oryginał (ang.)
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition. globenewswire.com 2024-12-23 10:45:00 Czytaj oryginał (ang.)
OptimizeRx initiated with an Equal Weight at Stephens Stephens initiated coverage of OptimizeRx with an Equal Weight rating and $5.50 price target. The firm says the company's "evolving" direct-to-consumer business model toward self-service may create headline risk to net revenue retention. Stephens still needs clarity on the company's return to growth and evolution of the business model that "cements OptimizeRx's place in the value chain." https://thefly.com 2024-12-19 18:25:31 Czytaj oryginał (ang.)
OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-11-18 09:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Steve Silvestro - President Conference Call Participants Ryan Daniels - William Blair & Company, LLC Sean Dodge - RBC Capital Markets Kyle Bauser - B. Riley Securities David Grossman - Stifel Financial Constantine Davides - Citizens JMP Stephanie Davis - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call. seekingalpha.com 2024-11-14 00:58:34 Czytaj oryginał (ang.)
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago. zacks.com 2024-11-13 20:35:29 Czytaj oryginał (ang.)
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains? OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2024-11-07 12:16:25 Czytaj oryginał (ang.)
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. globenewswire.com 2024-10-31 09:30:00 Czytaj oryginał (ang.)
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last? OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2024-10-03 09:26:10 Czytaj oryginał (ang.)
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initial program, however, ultimately resulted in a multi-solution, multi-brand engagement while DAAP conversion continues through the client's internal review and approval process. This engagement represents an ongoing expansion of investment by a top-tier pharma client in OptimizeRx's solutions and demonstrates the value of scaling them across several brands in its portfolio, driving stronger commercial performance from brands through HCP and DTC marketing alignment. globenewswire.com 2024-09-10 11:30:00 Czytaj oryginał (ang.)
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences The availability of Micro-Neighborhood ® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing globenewswire.com 2024-09-09 16:00:00 Czytaj oryginał (ang.)
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for OptimizeRx (OPRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com 2024-09-04 14:37:00 Czytaj oryginał (ang.)
OptimizeRx Corp. (OPRX) Tops Q2 Earnings Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago. zacks.com 2024-08-08 23:26:02 Czytaj oryginał (ang.)
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy? OptimizeRx (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-08-01 15:05:54 Czytaj oryginał (ang.)
OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. globenewswire.com 2024-07-25 11:30:00 Czytaj oryginał (ang.)
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program The Company's AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program globenewswire.com 2024-07-15 11:30:00 Czytaj oryginał (ang.)
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations • 84% of Patients Arrive at Doctor Visits Underinformed • Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies•  OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client globenewswire.com 2024-06-20 11:30:00 Czytaj oryginał (ang.)
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2024 Earnings Conference Call May 14, 2024 2:30 PM ET Company Participants William Febbo - CEO Edward Stelmakh - CFO Steve Silvestro - President Andrew D'Silva - SVP of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Eric Martinuzzi - Lake Street David Grossman - Stifel Constantine Davides - Citizen JMP Stephanie Davis - Barclays William Wood - B. Riley Securities Operator Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion. seekingalpha.com 2024-05-15 03:21:09 Czytaj oryginał (ang.)
OptimizeRx Reports First Quarter 2024 Financial Results WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period. globenewswire.com 2024-05-14 20:01:00 Czytaj oryginał (ang.)
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect? The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-05-13 15:01:25 Czytaj oryginał (ang.)
OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-05-06 20:30:00 Czytaj oryginał (ang.)